SCHEMBL1074891

SCHEMBL1074891

Cc1noc(NC(=O)N2CCC(=Cc3cccc(C(C)(F)F)c3)C(C)C2)c1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.34
CYP3A4 P08684 4/20 0.34
CYP2D6 P10635 4/20 0.34
ENPP2 Q13822 1/20 0.33
FAAH O00519 1/20 0.33
GABRA1 P14867 1/20 0.33
ADRA2C P18825 1/20 0.33
CNR1 P21554 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
CNR2 P34972 1/20 0.33
HTR2B P41595 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
CRHR1 P34998 1/20 0.32
FLT1 P17948 1/20 0.32
KDR P35968 1/20 0.32
EDNRA P25101 1/20 0.32
P2RY1 P47900 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1074887 1.00 LMNA (0.34) LMNACYP3A4CYP2D6ENPP2FAAH
SCHEMBL1032437 0.94 LMNA (0.40) LMNACYP3A4CYP2D6FAAHGABRA1
SCHEMBL1032435 0.94 LMNA (0.40) LMNACYP3A4CYP2D6FAAHGABRA1
SCHEMBL1031090 0.88 EDNRB (0.39) LMNAENPP2EDNRAP2RY1MEN1
SCHEMBL1031089 0.88 EDNRB (0.39) LMNAENPP2EDNRAP2RY1MEN1
SCHEMBL1036470 0.88 CYP3A4 (0.36) LMNACYP3A4CYP2D6ENPP2FAAH
SCHEMBL1036472 0.88 CYP3A4 (0.36) LMNACYP3A4CYP2D6ENPP2FAAH
SCHEMBL1034495 0.88 RAB9A (0.37) ENPP2EDNRAPOLBCASR
SCHEMBL1034493 0.88 RAB9A (0.37) ENPP2EDNRAPOLBCASR
SCHEMBL1037333 0.87 ENPP2 (0.37) LMNACYP3A4CYP2D6ENPP2FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053950-A1 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER, INC. 2011-03-03 US claimed
EP-2276734-A1 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS Pfizer Inc. (US) 2011-01-26 EP claimed
WO-2009127946-A1 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER INC. (US) 2009-10-22 WO claimed
US-20110053950-A1 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER, INC. 2011-03-03 US disclosed
EP-2276734-A1 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS Pfizer Inc. (US) 2011-01-26 EP disclosed
WO-2009127946-A1 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER INC. (US) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053950-A1 4-BENZYLIDENE-3-METHYLPIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS FAAH, FAAH2, CNR2 LMNA 3699/4885CYP3A4 288/4885CYP2D6 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.